# Updating Predictive Model for Cisplatin-Induced Acute Kidney Injury: Incorporating Concomitant Medications and the Standard Supportive Care

**Authors:** Kazuki Saito, Satoru Nihei, Junichi Asaka, Kenzo Kudo

PMC · DOI: 10.1155/ijne/6615898 · International Journal of Nephrology · 2025-10-14

## TL;DR

This study improves a model predicting kidney damage from cisplatin by adding the effect of concomitant medications, particularly magnesium supplementation.

## Contribution

The study introduces concomitant medications, especially magnesium supplementation, as a novel predictor in C-AKI prediction models.

## Key findings

- The existing model had poor performance with a C-statistic of 0.621.
- Adding magnesium supplementation improved the C-statistic to 0.695.
- The updated model showed a net reclassification improvement of 0.143.

## Abstract

Cisplatin-induced acute kidney injury (C-AKI) is detrimental to adequate cancer treatment. While scoring systems to predict C-AKI are available, they do not account for the impact of concomitant medications. This study aimed to enhance the predictive model by incorporating concomitant medications as a new predictor.

We included data from 1785 patients who received cisplatin at Iwate Medical University Hospital between April 2014 and March 2023. Initially, we assessed the performance of the existing model in our cohort. We then explored additional predictors to improve their discriminatory ability guided by the Akaike information criterion. Candidates for new predictors were concomitant anticancer and supportive care medications that were previously unexamined. Finally, we assessed the statistical usefulness of the updated model using the C-statistic and its clinical usefulness using net reclassification improvement (NRI) and decision curve analysis (DCA).

The discriminatory power of the existing model was poor, with a C-statistics of 0.621 (95% confidence interval [CI]: 0.582–0.660). Incorporating magnesium supplementation as a novel predictor significantly improved the model's performance, increasing the C-statistic to 0.695 (95% CI: 0.660–0.731). The updated model demonstrated a superior NRI of 0.143 (95% CI: 0.043–0.243). In the DCA, the updated model yielded higher net benefits for most threshold probabilities.

The existing model did not demonstrate satisfactory clinical performance in our cohort. While incorporating magnesium supplementation significantly improved model discrimination, its status as standard care limits its utility as a predictive variable. These findings underscore the necessity of developing C-AKI prediction models within cohorts receiving uniform, contemporary supportive care regimens.

## Linked entities

- **Chemicals:** cisplatin (PubChem CID 5460033), magnesium (PubChem CID 5462224)
- **Diseases:** acute kidney injury (MONDO:0002492)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), Acute Kidney Injury (MESH:D058186)
- **Chemicals:** Cisplatin (MESH:D002945), magnesium (MESH:D008274)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12539992/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12539992/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12539992/full.md

---
Source: https://tomesphere.com/paper/PMC12539992